ZENTIVA S.A. (SCD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZENTIVA S.A. (SCD) has a cash flow conversion efficiency ratio of 0.012x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON18.49 Million ≈ $4.24 Million USD) by net assets (RON1.50 Billion ≈ $343.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ZENTIVA S.A. market cap and net worth for the company's overall valuation and market capitalisation.
ZENTIVA S.A. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ZENTIVA S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ZENTIVA S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZENTIVA S.A. ranked by their cash flow conversion efficiency. Explore SCD operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dometic Group AB (publ)
ST:DOM
|
-0.002x |
|
Faeth Therapeutics, Inc.
NASDAQ:FTH
|
-0.091x |
|
Depo Auto Parts Industrial Co Ltd
TW:6605
|
0.051x |
|
Ceigall India
NSE:CEIGALL
|
-0.081x |
|
Canadian Solar Inc
NASDAQ:CSIQ
|
-0.026x |
|
TSRC Corp
TW:2103
|
0.027x |
|
Genomma Lab Internacional S.A.B. de C.V
MX:LABB
|
-0.020x |
|
Global Infotech Co Ltd
SHE:300465
|
0.347x |
Annual Cash Flow Conversion Efficiency for ZENTIVA S.A. (2019–2024)
The table below shows the annual cash flow conversion efficiency of ZENTIVA S.A. from 2019 to 2024. View ZENTIVA S.A. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | RON1.44 Billion ≈ $331.01 Million |
RON85.10 Million ≈ $19.54 Million |
0.059x | +395.83% |
| 2023-09-30 | RON1.19 Billion ≈ $273.53 Million |
RON14.18 Million ≈ $3.26 Million |
0.012x | -42.22% |
| 2022-09-30 | RON999.35 Million ≈ $229.47 Million |
RON20.59 Million ≈ $4.73 Million |
0.021x | -90.37% |
| 2021-09-30 | RON890.77 Million ≈ $204.54 Million |
RON190.64 Million ≈ $43.77 Million |
0.214x | +292.19% |
| 2020-09-30 | RON785.36 Million ≈ $180.33 Million |
RON42.86 Million ≈ $9.84 Million |
0.055x | +283.52% |
| 2019-09-30 | RON702.00 Million ≈ $161.19 Million |
RON-20.87 Million ≈ $-4.79 Million |
-0.030x | -- |
About ZENTIVA S.A.
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respir… Read more